A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Sponsor: National Cancer Institute NCI
Enrolling: Male and Female Patients
IRB Number: AAAT5906
U.S. Govt. ID: NCT03816345
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cancers include: bladder cancer, cervical cancer, head and neck/oral cancers, kidney cancer, adrenal cancer, liver cancer, lung cancer, lymphoma, and skin cancer (melanoma).
This study is closed
Brian Henick, MD
Do You Qualify?
Are you age 18 or older? Yes No
Do you have an autoimmune disease such as rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease? Yes No
Do you have a tumor that is metastatic or unresectable? Yes No
Are you able to make extra visits to the clinic for treatment and evaluations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator